Novel Agent N-803 Safe, Effective for BCG-Unresponsive High-Risk NMIBC
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
A new cancer diagnosis is independently associated with a higher risk of cardiovascular death, stroke, heart failure, and pulmonary embolism.
Men of African ancestry had the highest risk of developing metastatic prostate cancer when compared with men of other ancestries.
The excess risk of cancer appeared to be associated with the severity of heart failure.
An update to active surveillance recommendations has some physicians concerned.
Certain treatments were associated with an increased risk of death unrelated to testicular cancer.